SLV308 for Treatment of Patients With Early Parkinson's Disease
A Randomized, Double Blind, Placebo Controlled Parallel-Group Fixed and Flexible SLV308 Dose Arm Study to Assess Efficacy and Safety of SLV308 Monotherapy in the Treatment of Patients With Early Stage Parkinson's Disease
Sponsor: Solvay Pharmaceuticals
Listed as NCT00269516, this PHASE3 trial focuses on Early Stage Parkinson's Disease and remains completed. Sponsored by Solvay Pharmaceuticals, it has been updated 8 times since 2006, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Nov 2025 — Present [monthly]
Completed PHASE3
-
Sep 2025 — Nov 2025 [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
▶ Show 3 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Jun 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Solvay Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aguascalientes, Mexico , Ashville, United States , Bangalore, India , Barrie, Canada , Barrios Altos-Lima, Peru , Belgrade, Serbia , Bingham Farms, United States , Bogotá, Colombia , Brasov, Romania , Bratislava, Slovakia and 92 more locations